Key result
Sutureless SAVR shows comparable short-term survival to transapical TAVR in matched patients.
Why the study?
Despite expanding indications for TAVR, some patients remain ineligible, prompting a need to compare sutureless SAVR with transapical TAVR in patients unsuitable for transfemoral access.
Does sutureless surgical aortic valve replacement provide similar outcomes to transapical TAVR in patients with aortic valve disease ineligible for transfemoral access?
Observational (n=112)
No
Does sutureless surgical aortic valve replacement provide similar outcomes to transapical TAVR in patients with aortic valve disease ineligible for transfemoral access?
Sutureless aortic valve replacement is a feasible and hemodynamically comparable alternative to transapical TAVR for patients ineligible for transfemoral access.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for sutureless SAVR in transfemoral-ineligible patients; leaves open randomized confirmation before practice change.
BACKGROUND: The rapid development of transcatheter treatment methods has made transcatheter aortic valve replacement (TAVR) a feasible alternative to conventional surgical aortic valve replacement (SAVR). Recently, indications for TAVR have been expanded to intermediate- and low-risk patients, although there still remains a portion of ineligible patients. We sought to evaluate and compare our experience with sutureless SAVR and transapical TAVR in the "grey-area" of patients unsuitable for transfemoral access. METHODS: Between April 2018 and June 2021, 248 consecutive patients underwent a sutureless SAVR (SU-SAVR) or TA-TAVR at our institution. We performed a pair-matched analysis and identified 56 patient pairs based on the EuroSCORE II. All transcatheter procedures were performed using SAPIEN XT/3™ prostheses, while all surgical procedures deployed the Perceval (LivaNova) aortic valve. RESULTS: All patients presented with multiple comorbidities as reflected by the median EuroSCORE-II of 3.1% (IQR 1.9-5.3). Thirty-four patients from the surgical group (60.7%) underwent a concomitant myocardial revascularization. There was no significant difference in major adverse events, pacemaker implantation or postoperative mortality during follow-up. Both interventions demonstrated technical success with similar mean postoperative pressure gradients at follow-up and no cases of paravalvular leakage. CONCLUSIONS: Sutureless aortic valve replacement constitutes a feasible treatment alternative for patients with aortic valve disease who are ineligible for transfemoral access route and/or require concomitant coronary revascularization. With its excellent hemodynamic performance, similar survival compared to TA-TAVR, and high cost-efficiency without compromising the postoperative outcomes and in-hospital length of stay SU-AVR might be considered for patients in the "grey-area" between TAVR and SAVR.
No takes yet. Share an insight, caveat, or question.
Zubarevich et al. (2022) conducted an observational in Symptomatic moderate-to-severe aortic valve stenosis or regurgitation ineligible for transfemoral TAVR (n=112). Sutureless surgical aortic valve replacement (SU-AVR) with Perceval prosthesis vs. Transapical transcatheter aortic valve replacement (TA-TAVR) with SAPIEN XT/3 prosthesis was evaluated on 30-day and 6-month mortality (p=>0.05). Sutureless surgical aortic valve replacement achieved a 1.8% 30-day mortality rate and showed no significant difference in survival compared to transapical TAVR in matched patients.
Synapse has enriched 10 related papers. Consider them for comparative context: